SEC EDGARSEP 181 min read$CBLL

Chao Xingjuan sold $522K of CBLL

Chao Xingjuan (President and CEO) sold 20,846 shares of Ceribell, Inc. (CBLL) at $25.03 ($0.52M total) on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Chao Xingjuan

Published Sep 18, 2026, 12:45 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 18, 2026, 1:03 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$CBLL

Neutral

high confidence

Mentioned

$CBLL

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$CBLLNeutralLow

Why it matters

The sale is modest and pre‑arranged, likely having negligible effect on CBLL's stock price.

Market read

Routine insider sale; low trading relevance.

What to watch

Potential tax planning or diversification motives behind the 10b5‑1 sale.

Relevance 4/10Novelty 4/10Timing: post‑market 2026‑09‑15

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the sale.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CBLLNeutralHigh confidence

Context

President & CEO Chao Xingjuan sold 20,846 shares for $521,775.38 via a 10b5‑1 plan on 2026‑09‑15.

Expected impact

Minimal short‑term impact; price likely unchanged unless cumulative insider sales increase.

Evidence & confidence

The transaction size (≈0.07% of holdings) is small and pre‑arranged, limiting market reaction.

Market effects

Sector

No broader sector impact; insider sales are company‑specific.

Regional

Limited to Ceribell shareholders; no regional effect.

Global

None

Counterpoint

What could challenge this read

If the CEO is cashing out, it could hint at upcoming challenges not yet public.

Key entities

Company
Ceribell, Inc.
Medical device company developing rapid diagnostic platforms.
Executive
Chao Xingjuan
President and CEO of Ceribell, filing insider sale.

Read at source ← All news

SEP 17

$BLSMHighAI 8/10

Biotech Stocks At 52-Week Highs - BLSM +18% On Positive Trial Data, ADPT, ILMN, CBLL, NEOG

Biotech stocks BLSM, NEOG, ILMN, CBLL, and ADPT hit 52-week highs. BLSM rose 18% on positive trial data, NEOG grew 2% with Q4 revenue of $225M, ILMN reached $236 on 9.5% Q2 growth, CBLL hit $25.63 with Q2 revenue up 33%, and ADPT climbed 3% with full-year revenue forecast between $268M-$278M.

rttnews.com3 min

AUG 15

$LNTHMed

Weekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals

Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.

rttnews.com7 min

AUG 10

$CBLLHigh

Ceribell, Inc. (CBLL): Results of Operations and Financial Condition

Ceribell, Inc. (CBLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ceribell Reports Second Quarter 2026 Financial Results Sunnyvale, Calif. – August 10, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today repor

SEC EDGAR 8-K6 min

AUG 10

$CBLLMedAI 8/10

Ceribell Secures FDA Clearance For Advanced EEG AI Enhancements

Ceribell (CBLL) said the U.S. FDA granted 510(k) clearance for two AI enhancements in its cloud Neurology Portal: epileptiform abnormality detection and artifact reduction. The company says the updates improve EEG signal interpretation and reduce review time. CBLL shares closed Aug. 7, 2026 at $18.81, up 3.07%.

rttnews.com4 min

AUG 3

$CBLLMedAI 8/10

CeriBell stock rises after securing Medicare payment approval

CeriBell Inc. (NASDAQ:CBLL) shares rose about 3% after CMS approved a New Technology Add-on Payment for its Delirium Monitor System. The NTAP allows up to $2,171 per eligible Medicare patient case, starting Oct. 1, 2026, following FDA 510(k) clearance in Dec. 2025.

investing.com3 min

MAY 26

$CBLLMed

Manni Joseph S. sold $25K of CBLL

Manni Joseph S. (Chief Revenue Officer) sold 1,378 shares of Ceribell, Inc. (CBLL) at $18.00 on 2026-05-21.

SEC EDGAR2 min